生物標記市場規模、佔有率及成長分析（按產品、類型、研究領域、技術、適應症、應用、最終用戶和地區）－2025 年至 2032 年產業預測

預計生物標記市場規模將在 2023 年達到 582 億美元，從 2024 年的 660.6 億美元成長到 2032 年的 1819.2 億美元，預測期內（2025-2032 年）的複合年成長率為 13.5%。

生物標記市場正在經歷強勁成長，主要原因是慢性病的增加、技術進步以及個人化醫療需求的增加。隨著全球患者數量的增加，使用生物標記進行有效的早期檢測、監測和診斷的需求也日益增加。蛋白質體學、基因組學和代謝體學技術的創新正在加速新物標記的發現，進一步推動市場擴張。然而，開發和檢驗生物標記的成本高昂以及公眾對其益處的認知有限等挑戰可能會阻礙其發展。儘管存在這些障礙，個體化醫療和持續的技術進步仍然帶來了大量機會，使生物標記市場具備了開發和投資的條件。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 宏觀經濟指標
• 價值鏈分析
• 定價分析
• 專利分析
• 監管分析
• 技術分析
• 案例研究
• 客戶和購買標準分析

按產品/服務分類的生物標誌市場規模

• 市場概覽
• 耗材
  • 檢測試劑套件
  • 試劑和化學品
  • 列和過濾器
• 服務
• 軟體

生物標記市場規模（按類型）

• 市場概覽
• 安全生物標記
• 療效生物標記
  • 預測性生物標記
  • 替代生物標記
  • 動態物標誌物
  • 預測性生物標記
• 檢驗生物標記

按研究領域分類的生物標記市場規模

• 市場概覽
• 基因組學
• 蛋白質體學
• 代謝體學
• 其他研究領域

生物標記市場規模（按技術分類）

• 市場概覽
• 免疫檢測
  • ELISA
  • 蛋白質微陣列
  • 蛋白質印跡法
• NGS
• PCR
• 質譜法
• 層析法
• 其他技術

生物標記市場規模（依適應症分類）

• 市場概覽
• 癌症
• 感染疾病
• 免疫系統疾病
• 神經系統疾病
• 心血管疾病
• 其他疾病適應症

生物標記市場規模（按應用）

• 市場概覽
• 臨床診斷
• 藥物研發
• 個人化醫療
• 臨床研究
• 其他用途

生物標記市場規模（按最終用戶分類）

• 市場概覽
• 製藥和生物技術公司
• 醫院和診斷實驗室
• 學術研究所
• 其他最終用戶

生物標誌市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Hoffmann-La Roche AG（Switzerland）
• Thermo Fisher Scientific Inc.（United States）
• Agilent Technologies, Inc.（United States）
• QIAGEN NV（Netherlands）
• Bio-Rad Laboratories, Inc.（United States）
• Merck & Co., Inc.（United States）
• PerkinElmer, Inc.（United States）
• Illumina, Inc.（United States）
• BD（Becton, Dickinson and Company）（United States）
• Myriad Genetics, Inc.（United States）
• Siemens Healthineers AG（Germany）
• Danaher Corporation（United States）
• Biomerieux SA（France）
• Waters Corporation（United States）
• Abbott Laboratories（United States）
• Sysmex Corporation（Japan）
• Bio-Techne Corporation（United States）
• Charles River Laboratories International, Inc.（United States）
• Eurofins Scientific SE（Luxembourg）

結論和建議

Biomarkers Market size was valued at USD 58.2 billion in 2023 and is poised to grow from USD 66.06 billion in 2024 to USD 181.92 billion by 2032, growing at a CAGR of 13.5% during the forecast period (2025-2032).

The biomarkers market is experiencing robust growth, primarily fueled by the increasing prevalence of chronic diseases, advancements in technology, and a growing demand for personalized medicine. As global patient numbers rise, the need for effective early detection, monitoring, and diagnosis through biomarkers is intensifying. Innovations in proteomic, genomic, and metabolomics technologies are facilitating the discovery of new biomarkers, further propelling market expansion. However, challenges such as high costs associated with biomarker development and validation, as well as limited public awareness regarding their benefits, may hinder growth. Despite these obstacles, opportunities abound in the form of tailored medicine and continued technological advancements, making the biomarkers market ripe for development and investment.

Top-down and bottom-up approaches were used to estimate and validate the size of the Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Biomarkers Market Segments Analysis

Global Biomarkers Market is segmented by Product, Type, Research Area, Technology, Disease Indication, Application, End User and region. Based on Product, the market is segmented into Consumables, Services and Software. Based on Type, the market is segmented into Safety Biomarkers, Efficacy Biomarkers and Validation Biomarkers. Based on Research Area, the market is segmented into Genomics, Proteomics, Metabolomics and Other Research Areas. Based on Technology, the market is segmented into Immunoassays, NGS, PCR, Mass Spectrometry,Chromatographyand Other Technologies. Based on Disease Indication, the market is segmented into Cancer, Infectious Diseases, Immunological Disorders, Neurological Disorders, Cardiovascular Disorders and Other Disease Indications. Based on Application, the market is segmented into Clinical Diagnostics, Drug Discovery & Development, Personalized Medicine, Clinical Research and Other Applications. Based on End User, the market is segmented into Pharmaceutical & Biotechnology Companies, Hospitals & Diagnostic Laboratories, Academic & Research Institutes and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Biomarkers Market

The demand for biomarkers is rapidly increasing as healthcare shifts towards more personalized treatment approaches that consider the unique needs and genetic profiles of patients. This trend underscores the pivotal role of biomarkers in improving therapeutic outcomes. In recent years, the growth has been propelled by advanced research initiatives in biotechnology and molecular biology, which are facilitating the identification and application of novel biomarkers across various medical fields. As a result, there is a burgeoning interest in leveraging these biological indicators to tailor medical treatments, ultimately enhancing patient care and driving further innovation in the biomarkers market.

Restraints in the Biomarkers Market

The biomarkers market faces several significant challenges that could hinder its growth. Variability in biomarker testing methodologies and a lack of standardized practices across platforms can lead to inconsistent results, deterring widespread adoption. Additionally, the validation process for biomarkers associated with specific conditions and diseases often proves to be complex and time-consuming, further impeding progress. These hurdles not only slow the overall development of new biomarker technologies but also potentially restrict the market's expansion, as stakeholders may be hesitant to invest in uncertain outcomes or prolonged timelines for validation efforts.

Market Trends of the Biomarkers Market

The biomarker market is witnessing a significant trend towards the increased utilization of vitality biomarkers, which empower healthcare providers to assess patients' health proactively, even before symptoms manifest. This shift towards early intervention is crucial in averting the progression of various health conditions, thus enhancing patient outcomes. The integration of IoT devices and wearables into healthcare is further amplifying this trend, as these technologies enable continuous monitoring of vital health metrics in real-time. The resulting rich datasets not only facilitate personalized treatment plans but also bolster the quality of diagnostics, paving the way for innovative solutions in preventive medicine and chronic disease management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Patent Analysis
• Regulatory Analysis
• Technology Analysis
• Case Studies
• Customer And Buying Criteria Analysis

Global Biomarkers Market Size by Product & Service & CAGR (2025-2032)

• Market Overview
• Consumables
  • Assay Kits
  • Reagents & Chemicals
  • Columns & Filters
• Services
• Software

Global Biomarkers Market Size by Type & CAGR (2025-2032)

• Market Overview
• Safety Biomarkers
• Efficacy Biomarkers
  • Predictive Biomarkers
  • Surrogate Biomarkers
  • Pharmacodynamic Biomarkers
  • Prognostic Biomarkers
• Validation Biomarkers

Global Biomarkers Market Size by Research Area & CAGR (2025-2032)

• Market Overview
• Genomics
• Proteomics
• Metabolomics
• Other Research Areas

Global Biomarkers Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Immunoassays
  • ELISA
  • Protein Microarrays
  • Western Blot
• NGS
• PCR
• Mass Spectrometry
• Chromatography
• Other Technologies

Global Biomarkers Market Size by Disease Indication & CAGR (2025-2032)

• Market Overview
• Cancer
• Infectious Diseases
• Immunological Disorders
• Neurological Disorders
• Cardiovascular Disorders
• Other Disease Indications

Global Biomarkers Market Size by Application & CAGR (2025-2032)

• Market Overview
• Clinical Diagnostics
• Drug Discovery & Development
• Personalized Medicine
• Clinical Research
• Other Applications

Global Biomarkers Market Size by End User & CAGR (2025-2032)

• Market Overview
• Pharmaceutical & Biotechnology Companies
• Hospitals & Diagnostic Laboratories
• Academic & Research Institutes
• Other End Users

Global Biomarkers Market Size & CAGR (2025-2032)

• North America (Product & Service, Type, Research Area, Technology, Disease Indication, Application, End User)
  • US
  • Canada
• Europe (Product & Service, Type, Research Area, Technology, Disease Indication, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product & Service, Type, Research Area, Technology, Disease Indication, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product & Service, Type, Research Area, Technology, Disease Indication, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product & Service, Type, Research Area, Technology, Disease Indication, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BD (Becton, Dickinson and Company) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biomerieux SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Waters Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Techne Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories International, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific SE (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations